Redox (RDX) investor relations material

Opening remarks and agenda

• Chair Ian Campbell opened the meeting; the agenda covered the Chair’s introduction, CEO Raimond Coneliano’s FY26 review, stakeholder questions and formal business.

Financial performance review

• FY26 sales revenue reached AUD 1.330b, up 6.9% vs PCP; gross profit was AUD 298m, up 11.0%, and gross margin was 22.4%, up 0.8ppts.

• NPAT was AUD 92m, up 19.2%; EPS increased 20%, EBITDAFX was AUD 134m, up 9.9%, and after-tax ROIC was 14.6%, up 1.1ppts.

• North American sales grew 33.8% to more than AUD 100m; Australian sales rose 6.1% to AUD 1.120b.

• FY26 growth was primarily organic, supplemented by acquisitions, with subdued demand; selling prices were relatively flat YoY but increased half over half, alongside improved product mix.

• Q1 FY27 average selling prices were ~9% higher YoY, volumes broadly in line with PCP, and gross margins remained above FY26’s 22.4%.

Board and executive committee updates

• Ian Campbell’s retirement takes effect at the end of the AGM; Mary Verschuer is to succeed him as Chair, and Sheila Lines became an Independent Non-Executive Director on 1 September 2026.

• Sheila Lines was appointed after a search firm-led process; cited qualifications included financial expertise, commercial, operational and international experience, and ASX experience.

• Campbell highlighted orderly board and executive succession plans, external expertise and pursuit of acquisition opportunities as contributions during his tenure.

• Formal business included re-election of Renato Coneliano and Garry Wayling, election of Sheila Lines, and performance-rights grants to Raimond, Renato and Richard Coneliano.